Introducing the Next Generation
TAE Life Sciences is developing breakthrough technology for the clinical investigation of Boron Neutron Capture Therapy (BNCT) to provide a treatment option for patients with malignancies that are difficult to treat through traditional methods, such as head, neck and brain cancers. Our proprietary accelerator-based BNCT platform will combine two well-known modalities - biological targeting and radiation therapy - for precision treatment at the cellular level. TAE Life Sciences will bring this promising technology to the hospital setting, where it has previously been inaccessible.
Benefits of TAE Life Sciences BNCT
Our Neutron Source
* The device being developed by TAE Life Sciences is for investigational use only and has not been approved for sale or commercial use.
About Boron Neutron Capture Therapy
BNCT is a multi-step combination therapy. A cancer patient is first administered a boron target drug that preferentially binds to and carries non-toxic boron-10 to malignant cells. The tumor tissue is then showered with a beam of low energy neutrons at a level and spectrum optimal for reaction with the boron-10.
This reaction, inside the cells, emits charged particles that destroy the cell while limiting damage to surrounding healthy tissue without boron-10. Once the beam reacts with the boron in the cancer cells, the relative biological effectiveness (RBE) is significantly higher than in most other forms of radiation therapy.2
This secondary radiation reaction, with cellular-level precision, spares more healthy tissue and can potentially treat cancers that otherwise have few treatment options due to their proximity to critical tissue.1